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A number of in vitro and in vivo studies (for review see Kaye
& Merry, 1985) have shown that resistance to adriamycin
(doxorubicin; ADR) can be circumvented by the calcium
antagonist verapamil (VPM). This effect has been noted both
in animal and in human tumour lines and a clinical trial
investigating the value of this approach in human small cell
lung cancer is underway (Milroy et al., 1987). However,
concern has been expressed because the maximum clinically
achievable VPM levels in plasma (1-2pM) are somewhat
lower than those which are consistently active in vitro in
reversing ADR resistance (generally 6yM). A major
metabolite of VPM is the N-demethylated derivative norver-
apamil (NVPM; Figure 1) and following oral dosing NVPM
is present in plasma in equimolar concentrations to VPM
within 2-3h (Hamann et al., 1984a). If this metabolite were
active in the context of overcoming drug resistance the
effective concentration of modulating agent in vivo would be
increased and the clinical potential of verapamil might be
improved. In this short report we present data on the ability
of both VPM and NVPM to enhance sensitivity to ADR in
a murine tumour cell line.
MOG-XMT1 is a murine cell line derived from a tumour
arising at the site of implantation of a human small cell lung
cancer as a xenograft in an MFI-nu/Ola nude mouse. The
cell line was shown to be of murine origin by LDH
isoenzyme analysis (Hay, 1986) and karyotype. The cell line
was tumorigenic in immunocompetent mice giving rise to
well vascularised anaplastic tumours in which the
predominant cell type was epithelioid. The cells were grown
as monolayer cultures in RPMI 1640 supplemented with 10%
fetal calf serum and with a gas phase of 2% CO2 in air. Cell
suspensions were prepared by trypsinisation and counted
electronically using a Coulter ZB cell counter.
ADR was obtained from Farmitalia (Barnet, Herts, UK),
VPM was obtained from Abbot Laboratories
(Queensborough, Kent, UK) and NVPM was a gift from
Knoll AG (Ludwigshafen, FR Germany). Stock solutions
(2mgml ADR in isotonic lactose; 2.5mgml-I VPM or
NVPM in saline) were stored as frozen aliquots in the dark
until use (generally no longer than 3 weeks). 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (thiazolyl blue;
MTT) was obtained from Sigma (Poole, Dorset, UK).
In vitro cytotoxicity assays were performed using either
MTT reduction to the coloured formazan product
(Carmichael et al., 1987) or colony formation in monolayer
as end-points. Viability was expressed as percentage of
control and the concentration of drug causing a 50%
reduction (ID50) was determined graphically. To determine
toxicity appropriate controls containing VPM and/or NVPM
were included in all assays. Sensitisation ratios were
calculated as:
ADRID50-M
ADRID50 +M
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Figure 1 Structure of verapamil (R=CH3) and norverapamil
(R =H).
where M is the modulating agent (or combination of
modulating agents) employed in that particular assay.
Sensitisation ratios were calculated using cytotoxicity curves
derived from two to six replicates of five drug concentrations
within a single experiment and all experiments were repeated
at least three times.
For the MTT assay MOG-XMTI cells (200-1,000
cellswell-P in 200p1 culture medium) were seeded into 96-
well Linbro tissue culture plates (Flow Laboratories, Irvine,
UK). After 72h, ADR+VPM or NVPM was then added for
a further 24h. The cells were then allowed a recovery period
of 72h in the absence of drugs before MTT (50pl, 3mgmli-
in Dulbecco's PBS) was added to each well. After a further
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Figure 2 Typical experiments showing the effect of verapamil
and norverapamil on the sensitivity of MOG-XMT1 to
adriamycin as determined by MTT reduction. The bars represent
s.e.m. (n=6). (a) 0 O control without verapamil,
* * with 6.6gM verapamil; (b) O O control with-
out norverapamil, * * with 6.6pM norverapamil.
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Table I Summary of MTT assay results showing the effect
of verapamil and norverapamil on the sensitivity of MOG-
XMT1 to adriamycin
Concentration Sensitisation ratioa
of modulating (mean +s.e.m., n=3-5)
agent VPM NVPM VPM+NVPM
6.6IM 4.0+0.5 3.9+1.2 3.0+0.1
2.0gM 1.9+0.3 1.6+0.1 3.5+0.3
0.6,UM 1.0+0.3 0.8+0.2 1.8+0.5
ADRID50 without modulating agent
ADRID50 with modulating agent
4h incubation the resultant formazan crystals were dissolved
in DMSO (200pl) and optical density at 600nm (A600) was
determined using a Bio-Rad model 2550 EIA reader.
In the cloning experiments 500 MOG-XMT1 cells in 10ml
complete culture medium were added to 8cm Corning tissue
culture dishes (McQuilkin Instruments Ltd, Glasgow, UK)
in the presence of drugs or saline (control). The dishes were
incubated for 9-11 days, fixed in methanol, stained with
Giemsa and colonies of 16 or more cells were scored using a
dissecting microscope.
Preliminary experiments (with growth monitored by cell
counting) confirmed that under the conditions of the MTT
assays control cells remained in exponential growth for the
duration of the assay and that A600 was proportional to cell
number over the range 5-29 x 104 cellswell-1 (the maximum
cell concentration obtained at the end of the assay). VPM
and NVPM were non-toxic at the concentrations used in the
MTT experiments (ID50=79+161IM and 81+184uM for
VPM and NVPM respectively; mean +s.e.m., n =3).
Figure 2 shows the results of a typical MTT experiment.
The general shape of the curves were similar in all
experiments. In this case 6.6gM VPM and 6.6pM NVPM are
seen to produce sensitisation ratios of 3 and the difference in
absorbance at 56nM ADR is significant in both cases
(P<0.01; Student's t test). In replicate experiments a similar
difference between the curves was observed and no
significant toxicity with either modulating agent alone was
noted.
Table I summarises the results of our MTT experiments.
The ID50 of ADR in the absence of VPM was 106+15 nM
(mean+s.e.m., n= 13). The data show that the activity of
VPM and NVPM in enhancing sensitivity to ADR is dose-
dependent. It can also be seen that NVPM is equally active
to VPM and shows a similar dose-response relationship.
Furthermore at lower doses (0.6 and 2.0gM) the
combination of VPM and NVPM produced a greater effect
on ADR sensitivity than either modulating agent alone with
the difference being statistically significant (P<0.05;
Student's t test) at 2.0pM. At 6.6/IM, however, the addition
of NVPM to VPM did not increase the sensitisation ratio;
suggesting that the effect of either is maximal at this
concentration. In a separate series of experiments 2.0pM
VPM +0.6gM NVPM (the peak plasma concentrations
obtained in mice treated with the maximum tolerated dose of
VPM i.p.; Merry et al., 1988) produced a sensitisation ratio
of 2.4+0.5 (mean+s.e.m., n=3).
A similar dose-response curve (data not shown) for the
effect of VPM on ADR sensitivity in MOG-XMT1 was also
obtained using a previously described (Merry et al., 1984)
cytotoxicity assay with 3H-leucine incorporation as
end-point.
Figure 3 shows the results of typical cloning experiments.
In this case 6.6yM VPM and 6.6gM NVPM are seen to
produce sensitisation ratios of 22 and 6 respectively. Overall,
in our cloning experiments 6.6gM VPM and 6.6/UM NVPM
produced sensitisation ratios of 16.1+4.4 and 4.4+1.2
(mean+s.e.m., n=3) and there was a statistically significant
reduction (P<0.05, Student's t test) in colony formation
with 6.6gM VPM at 8.6nM ADR and 43nM ADR and with
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Figure 3 Typical experiments showing the effect of verapamil
and norverapamil on the sensitivity of MOG-XMT1 to
adriamycin as determined by colony formation. The lines join the
mean of duplicate determinations at each drug concentration. (a)
0 control without verapamil, * with 6.6/M verapamil; (b) 0
control without norverapamil, 0 with 6.6pM norverapamil.
6.6pM NVPM at 43nM ADR. The ID50 of ADR in the
absence of VPM was 40.3 +5.5nM (mean+s.e.m., n= 13) and
plating efficiency of untreated controls was 17.5+2.9%
(mean+s.e.m., n=11). Colony formation in the presence of
6.6pM VPM alone or 6.6pM NVPM alone was 83.9+4.4%
(mean+s.e.m., n=5) and 107.6+3.0% (mean+s.e.m., n=4)
respectively relative to untreated controls.
Thus the ability of 6.6pM VPM or NVPM to increase
sensitivity to ADR in this cell line has been confirmed in
monolayer cloning experiments although the relative efficacy
of VPM and NVPM in enhancing ADR sensitivity is more
difficult to assess in this assay than in the MTT experiments.
While the sensitisation ratio obtained with VPM was almost
4-fold that obtained with NVPM, 6.6gM VPM caused a
16% reduction in colony formation in the absence of ADR.
This contrasts with the absence of toxicity with either VPM
or NVPM in the MTT experiments or with NVPM in the
cloning experiments. The VPM toxicity seen in the cloning
experiments could be the result of the longer period of
exposure.
The plasma pharmacokinetics of VPM have been well
documented. It has been shown that plasma concentrations
of up to 6pM VPM may be achieved by intravenous infusion
(Ozols et al., 1987), but these are associated with significant
cardiovascular toxicity. Clinical trials (Benson et al., 1985;
Cantwell et al., 1985) have, however, shown that steady state
concentrations of VPM in plasma of 0.5-1/pM can be
maintained with limited toxicity. VPM concentrations that
have been used to effectively circumvent ADR resistance in
vitro (generally 6.6uM) are higher than clinically achievable
plasma levels (1-2,pM) and these disappointing results may
have previously dissuaded researchers from pursuing this
approach in the clinic.
Data from two sources, however, suggest that clinical
studies should proceed. First, Slater et al., (1982) have
shown that 1 guM VPM is active in overcoming daunorubicin
(a structural analogue of ADR) resistance in Ehrlich ascites
carcinoma. Second, achievable tissue levels of VPM and
NVPM may be greater than achievable plasma levels. Data
on tissue levels is limited, but Hamann et al. (1984b) have
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reported that levels of 2-50pg VPMg-1 tissue and 10-50pg
NVPM g- tissue in lung, liver, kidney and heart from rats
treated with 30mgkg- VPM i.p. These levels were
maintained for at least 4h (the duration of the experiment).
While it is acknowledged that the pharmacodynamics of
exposure of cells to VPM and NVPM in this in vitro study
may be dissimilar to those encountered in vivo, the
concentration x time product of the 24h exposure to 0.6-
6.6pM (0.3-3.2pgml-P) VPM or NVPM used in our MTT
assay may approximate that found in normal rat tissues (see
above). Furthermore, in the cloning experiments (in which
cells were exposed to 6.6pM VPM or NVPM for 9-11 days)
circumvention of ADR resistance was also seen. The
demonstration that VPM and NVPM can circumvent ADR
resistance using two different experimental protocols (with
different end-points and conditions of drug exposure)
reduces the likelihood that this phenomenon is an
experimental artefact.
Previous studies from this department (Kerr et al., 1986;
Merry et al., 1988) have also shown that the metabolite
NVPM is present in approximately equal concentrations to
VPM in the plasma of patients treated with oral VPM and is
also present in significant amounts in the plasma of mice
treated with VPM i.p. It is also important to note that, while
NVPM may contribute to the ability of VPM to circumvent
ADR resistance, the contribution of NVPM to the cardio-
vascular side-effects may be small. Naugebauer (1978) has
reported that NVPM has only 20% of the coronary
vasodilator activity of VPM in dogs. In this paper we have
shown that NVPM has a similar activity to VPM in
enhancing the sensitivity of a murine tumour cell line to
ADR in vitro and that at pharmacologically relevant concen-
trations NVPM can increase enhancement of sensitivity to
ADR caused by VPM. Plasma and tissue concentrations of
VPM may thus represent only half the potential modulating
activity and by ignoring the contribution of this metabolite
the clinical potential of VPM in overcoming ADR resistance
may have previously been significantly underestimated.
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